A compound that works is not the same as a compound you can explain. Mechanism of action, the targets that actually move, and whether a readout will translate are analysis questions, and they decide go or no-go long before the next study is designed.

The Mechanism of Action Package

For the stage gate where the intended target is no longer enough: it establishes what the compound actually does to the cell, which targets move on their own, and which move only downstream.

Mechanism-of-action transcriptomics, beyond the intended target
Target identification support, separating direct movement from downstream consequence
Screening readout analysis, to establish whether hits separate from noise reliably enough to act on
Translational biomarker pipelines, to judge early whether a model finding can travel

We are not a service provider taking an order and running a protocol. The design is ours: which off-target movements are signal and which are downstream consequence — a call that requires knowing the pathway, not just running the differential expression. That is what an R&D team working on the subject brings, and it is the difference between buying an analysis and running a programme.

The questions we take on

What the compound actually does to the cell, beyond the intended target
Which targets move, and which move only as a downstream consequence
Whether a screening readout separates hits from noise reliably enough to act on
Whether a biomarker seen in a model has any chance of translating

How the analysis runs

Mechanism-of-action transcriptomics

Dose and time series analysed as series, not as a set of isolated comparisons.

Target identification support

Ranking what moved, and separating cause from downstream consequence.

Screening readout analysis

Hit calling with the error rate stated, so a shortlist can be acted on.

Translational biomarker pipelines

Candidates carried from model to cohort with the same definitions throughout.

Reproducible reporting

Versions, parameters and thresholds recorded per study, ready for an internal review.

Working under confidentiality and stage gates

Analysis plans are scoped per stage gate, so results land in time for a go or no-go rather than after it.

Coded sample identifiers and NDA-governed workflows keep target and compound identity compartmentalized, and outputs are formatted to integrate with the informatics stack you already run rather than replace it.

What the report contains

Methods with exact tool versions, parameters and thresholds. QC and cohort-level figures. Statistical results. An interpretation written against the biological question you started from.

Built to be audited or reproduced by a third party.

Where the data comes from

The laboratory work behind these analyses runs on OMICS4, GenXMap’s platform site. Sample requirements, shipping and turnaround are published there.

We also take on data we did not generate. An existing dataset, from an earlier study or from another provider, is analysed on its own terms. What decides the work is the question and the metadata that comes with it, not who ran the sequencer.

Book the platforms on OMICS4

Drug Discovery & Biotechnology